Akari Therapeutics Plc

Akari Therapeutics Plc has filed its Definitive Proxy Statement for the 2026 Annual General Meeting (AGM) scheduled for June 30, 2026. The meeting will cover standard corporate business including the review of the 2025 annual report, director re-elections, and auditor appointments. Notably, shareholders will vote on resolutions related to share and warrant issuances under specific agreements and the authorization for directors to allot shares. The company urges shareholders to submit their proxies by June 26, 2026, with a separate deadline for ADS holders.

Akari Therapeutics released a CEO Corner segment discussing insights from the 2026 ASCO Annual Meeting and the company's strategic position in the evolving ADC landscape. CEO Abizer Gaslightwala highlighted the growing importance of novel ADC payloads for difficult-to-treat KRAS-driven cancers and the industry's shift towards "ADC 2.0." The segment featured preclinical data presented at ASCO, demonstrating synergy between Akari's PH1 spliceosome-modulating payload and a KRAS inhibitor in pancreatic cancer models. The company also outlined anticipated milestones, including the planned initiation of its Phase 1 first-in-human clinical trial for lead candidate AKTX-101 by mid-2027.

Akari Therapeutics' CEO, Abizer Gaslightwala, discussed promising preclinical data at the 2026 ASCO Annual Meeting, highlighting the synergy of AKTX-101 with a KRAS inhibitor in KRAS-mutated pancreatic cancer models. This data validates the company's differentiated spliceosome-modulating ADC platform and its PH1 payload, which aims to redefine treatment for difficult-to-treat KRAS-driven cancers. The company also outlined plans to initiate a Phase 1 first-in-human clinical trial for AKTX-101 by mid-2027.

Akari Therapeutics Plc entered into a securities purchase agreement to raise approximately $5.5 million in gross proceeds through a private placement. The company will sell 1,470,588 unregistered American Depository Shares (ADSs) or prefunded warrants, along with Series H, I, and J warrants, to certain investors. The net proceeds are intended for working capital and general corporate purposes, with the offering expected to close in three tranches by July 15, 2026.

Akari Therapeutics announced positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, presented at the ASCO Annual Meeting 2026. The data highlighted synergistic cytotoxic activity of AKTX-101 in combination with a KRAS inhibitor (adagrasib) in KRAS-mutated pancreatic cancer models. This synergy, not observed with conventional TROP2 ADCs, suggests a differentiated mechanism for Akari's PH1 RNA spliceosome-modulating payload and expands the potential therapeutic opportunity for AKTX-101 in difficult-to-treat KRAS-driven cancers. The company aims to initiate a Phase 1 clinical trial for AKTX-101 by mid-2027.

Akari Therapeutics Plc successfully priced a private placement financing round, expected to raise approximately $5.5 million in gross proceeds. These funds will primarily advance its lead ADC program, AKTX-101, towards a first-in-human Phase 1 clinical trial, and for general corporate purposes. The transaction involves the issuance and sale of 1,470,588 unregistered ADSs (or prefunded warrants) priced at $3.74 per ADS, along with unregistered Series H, I, and J Warrants, subject to shareholder approval. The gross proceeds will be funded in three separate closings between May 27, 2026, and July 15, 2026.

Akari Therapeutics Plc reported a significant net loss of $14.455 million for the three months ended March 31, 2026, a substantial increase from $3.705 million in the prior year. The loss was primarily driven by impairment charges totaling $12.130 million on goodwill and other intangible assets. The company also disclosed a going concern warning due to its accumulated deficit of $279.0 million and insufficient cash to fund operations for the next year. Additionally, Akari completed an ADS ratio change and regained compliance with Nasdaq's minimum bid price requirement.

Akari Therapeutics announced that its President and CEO, Abizer Gaslightwala, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. During the virtual event, management will discuss the company's differentiated antibody drug conjugate (ADC) pipeline, including its proprietary PH1 RNA splicing modulator payload platform and the lead TROP2-targeting ADC program, AKTX-101. The company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027.

Akari Therapeutics announced the grant of a major European patent (No. 3684773B1) for its proprietary Thailanstatin-based PH1 ADC payload platform. This patent provides broad composition-of-matter protection across numerous European countries, significantly strengthening the company's global intellectual property. The patent reinforces Akari's ability to develop a differentiated antibody-drug conjugate (ADC) pipeline, including lead candidate AKTX-101, which is in IND-enabling studies with a Phase 1 trial expected by mid-2027.

Akari Therapeutics Plc filed an S-1 registration statement for a public offering of up to 1,139,818 American Depositary Shares (ADSs) and accompanying Series H and Series I Warrants. The offering, on a best-efforts basis with no minimum, has an assumed combined public offering price of $6.58 per ADS and warrants, aiming for estimated maximum net proceeds of approximately $6.7 million. The company, a preclinical oncology firm with no product revenue, intends to use the proceeds for research and development, working capital, and general corporate purposes, noting existing cash is sufficient only through mid-2027 without these funds.